美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Invesco Nasdaq Biotechnology ETF

34.82

+0.34801.01%

盘后：34.820.00000.00%19:30 EDT

成交量：1.41万

成交额：48.94万

市值：9,679.96万

市盈率：- -

高：34.92

开：34.52

低：34.42

收：34.47

52周最高：36.84

52周最低：23.42

股本：278.00万

流通股本：278.00万

量比：0.80

换手率：0.51%

股息：0.26

股息率：0.74%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

ST人福：RFUS-949片进入II期临床试验研究

甘李药业(603087.SH)获得GZC8072片新适应症《药物临床试验批准通知书》

ETF日报(09.03)丨政策利好持续催化创新药板块 “小非农”数据爆冷短期支撑金价

甘李药业：GZC8072片获2型糖尿病临床试验批准

ST人福(600079.SH)：RFUS-949片进入II期临床试验研究

创新药概念局部回暖

A股创新药概念局部回暖，千金药业尾盘涨停，德展健康此前封板，诺诚健华、迪哲医药、百利天恒涨幅居前。

百奥赛图与齐鲁制药达成全人纳米抗体分子非排他授权合作，支持神经领域创新药物开发

国内创新药企中报归母净利增近九成！恒生创新药ETF华泰柏瑞（520500）连续2个交易日获资金加仓

创新药企密集进入临床数据验证期，石药集团涨超4%！华宝基金港股通创新药ETF（520880）再收半年线！

摩根大通投行联席负责人：并购交易业务有望迎来创纪录年份。

首个国产IL-17A/F双靶点抑制剂获批，这一40年来“有研究无产品”的靶点迎临床突破｜掘金创新药

每日经济新闻

创新药半年报冰火两重天：百济神州一款药卖了161亿元、六成药企还在求生，“卖药”仍是终极命题

每日经济新闻

欧康维视生物-B(01477)：OT-211 III期临床试验完成患者入组

安进（AMGN）罕见病药物Tavneos将于27年3月1日被彻底撤销英国上市许可

海西新药：已提交自研创新药HX9428临床试验申请

诺华集团：高效口服BTK抑制剂瑞米布替尼在III期RMS临床试验中显著降低复发率安全性表现良好

众生药业(002317.SZ)：昂拉地韦片新增适应症临床试验申请获受理

国家药监局正式启动滴眼剂一致性评价工作

高盛9月“确信名单”更新：美股纳入福泰制药(VRTX.US) 欧股力推莱茵、Adyen和塔兰克斯

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/IBBQ/news?page=9"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.82,"timestamp":1789416000000,"preClose":34.472,"halted":0,"volume":14094,"hourTrading":{"tag":"盘后","latestPrice":34.82,"preClose":34.82,"latestTime":"19:30 EDT","volume":36,"amount":1244.0123,"timestamp":1789428600873,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01009514968670222,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"已收盘","change":0.348,"latestTime":"09-14 16:00:00 EDT","open":34.52,"high":34.92,"low":34.42,"amount":489401.81775,"amplitude":0.014505,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":34.472,"sharesOutstanding":2520001,"nav":34.43989,"aum":95742928.63989,"dividendRate":0.007412,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.82,"preClose":34.82,"latestTime":"19:30 EDT","volume":36,"amount":1244.0123,"timestamp":1789428600873,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.801497,"impliedVol":0.1149,"impliedVolPercentile":0.4861},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.801497,"shares":2780001,"dividePrice":0.2581,"high":34.92,"amplitude":0.014505,"preClose":34.472,"low":34.42,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.82,"eps":0,"divideRate":0.007412,"volume":14094,"delay":0,"ttmEps":0,"open":34.52,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":36.05,"twentyDayClose":33.8122,"sixtyDayClose":29.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664820856","title":"ST人福：RFUS-949片进入II期临床试验研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664820856","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664820856?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 16:37","pubTimestamp":1788424652,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","BMED","MDTX","IBBQ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664270568","title":"甘李药业(603087.SH)获得GZC8072片新适应症《药物临床试验批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664270568","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664270568?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 16:31","pubTimestamp":1788424286,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)发布公告，公司全资子公司甘李药业山东有限公司于近日收到国家药品监督管理局下发的关于在研药品GZC8072片的《药物临床试验批准通知书》，同意本品开展2型糖尿病适应症的临床试验。GZC8072片是甘李药业自主研发的新一代偏向型超长效多肽口服周制剂。该分子依托公司NovaPeptide多肽技术平台与SupOraTide口服多肽技术平台，在提升分子活性、延长半衰期的基础上，同时显著改善口服生物利用度，从而有望支持每周一次口服给药的方案。截至公告披露日，全球范围内尚无用于2型糖尿病的GLP-1口服周制剂片剂获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","PSYK","BK0239","BMED","IBBJ","603087","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664820831","title":"ETF日报(09.03)丨政策利好持续催化创新药板块 “小非农”数据爆冷短期支撑金价","url":"https://stock-news.laohu8.com/highlight/detail?id=2664820831","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664820831?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 16:30","pubTimestamp":1788424202,"startTime":"0","endTime":"0","summary":"国家医保局政策释放利好信号，创新药板块表现突出；美国ADP就业数据不及预期影响，黄金股相关ETF集体回升。截至收盘，恒生指数跌0.39%，报25213.31点，全日成交额1993.82亿港元；恒生科技指数跌1.08%，报4468.48点。国家医保局召开新闻发布会，发布按病种付费3.0版分组方案和技术规范，这一举措被视为对创新药板块的直接利好。因第二季净息差有所改善，信达国际短期看好内银股。中信证券表示，7月底以来，海外发达市场国债收益率普遍飙升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MGCmain","DUST","GDXD","GLDM","CERY","LNGR","OUNZ","IAU","UGL","UYM","CMDT","GBUG","RING","FGLD","GDX","CEF","AAAU","PALL","GCmain","NANR","PYZ","SGDJ","02840","IAUI","EPU","BEGS","MEDX","DZZ","IAUM","BTGD","SGOL","DBC","GDE","XLBI","FGDL","GOAU","YGLD","DGP","BAR","SGDM","06978","IBBQ","SHNY","159992","JNUG","SImain","USG","GDXY","DULL","VGFPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664716827","title":"甘李药业：GZC8072片获2型糖尿病临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664716827","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664716827?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 16:29","pubTimestamp":1788424183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","IBBQ","IBBJ","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664279758","title":"ST人福(600079.SH)：RFUS-949片进入II期临床试验研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664279758","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664279758?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 16:12","pubTimestamp":1788423169,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST人福(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”，公司持有其80%的股权)研发的RFUS-949片近日进入II期临床试验研究。试验名称：评价RFUS-949片用于腹部手术术后镇痛的多中心、随机、双盲、平行、安慰剂对照的疗效和安全性研究试验目的：评价RFUS-949片用于术后镇痛的疗效和安全性，探索RFUS-949片用于术后镇痛的用法用量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0070","IBBQ","BK0096","600079","IBBJ","PSYK","BK0188","BMED","BK0028","BK0239","BK0185","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664242468","title":"创新药概念局部回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2664242468","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664242468?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 14:59","pubTimestamp":1788418780,"startTime":"0","endTime":"0","summary":"创新药概念局部回暖","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864003250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864003250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","MEDX","06978","BK1161","BK1574","LNGR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664245108","title":"A股创新药概念局部回暖，千金药业尾盘涨停，德展健康此前封板，诺诚健华、迪哲医药、百利天恒涨幅居前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664245108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664245108?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 14:58","pubTimestamp":1788418691,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664782740","title":"百奥赛图与齐鲁制药达成全人纳米抗体分子非排他授权合作，支持神经领域创新药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2664782740","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664782740?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 14:23","pubTimestamp":1788416580,"startTime":"0","endTime":"0","summary":"北京2026年9月3日 /美通社/ -- 百奥赛图（北京）医药科技股份有限公司于2026年9月2日宣布，公司近期与齐鲁制药有限公司签署全人纳米抗体分子非排他授权合作协议。根据协议，百奥赛图将向齐鲁制药授权一款全人纳米抗体分子，用于支持其在神经领域创新药物项目中的研发探索。通过此次授权，齐鲁制药可结合其自身研发策略，对相关纳米抗体分子开展进一步研究和开发，后续项目的开发形式将根据项目特点和治疗需求灵活推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5039953_ZH39953_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5039953_ZH39953_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["688796","BK1191","06978","IBBQ","01477","02315","MEDX","BK1161","BK0216","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664500829","title":"国内创新药企中报归母净利增近九成！恒生创新药ETF华泰柏瑞（520500）连续2个交易日获资金加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2664500829","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664500829?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 13:37","pubTimestamp":1788413820,"startTime":"0","endTime":"0","summary":"全球创新药领域近期迎来密集催化。国内创新药企中报季业绩密集兑现。目前A股市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞已连续2个交易日获得资金净流入，7月以来日均成交额高达20.15亿元，最新份额、规模分别为18.99亿份、26.97亿元。华泰柏瑞基金是国内首批ETF管理人，在指数投资领域深耕超19年，为投资者打造了沪深300ETF华泰柏瑞、A500ETF华泰柏瑞等投向透明、交易便捷、费率低廉的指数工具。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-09-03/doc-iniqpqxy2132359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","IBBQ","06978","LNGR","MEDX","520500","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664231028","title":"创新药企密集进入临床数据验证期，石药集团涨超4%！华宝基金港股通创新药ETF（520880）再收半年线！","url":"https://stock-news.laohu8.com/highlight/detail?id=2664231028","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664231028?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 10:52","pubTimestamp":1788403920,"startTime":"0","endTime":"0","summary":"9月3日，港股创新药链继续活跃，创新药龙头公司领涨，石药集团、中国生物制药双双涨超4%。纯正创新药指数——恒生港股通创新药精选指数一度冲高逾2%，跟踪该指数的港股通创新药ETF华宝盘中再收半年线。中金公司提示，创新药较多公司进入临床数据验证阶段，值得自下而上关注。据统计，港股通创新药ETF华宝覆盖的48家创新药研发公司中，31家上半年实现盈利，归母净利同比正增长的有33家，占比近7成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-03/doc-iniqpkry1034045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2039709279.SGD","01093","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU0501845795.SGD","IE0008368742.USD","LU1226288170.HKD","IE00B031HY20.USD","LU0326950275.SGD","LU0140636845.USD","LU1152091168.USD","LU1993786604.SGD","BK1515","IBBQ","LU1152091754.HKD","LU1226287529.USD","159992","LU1226288253.USD","LU1328277881.USD","IE0008369823.USD","LNGR","LU1813983027.USD","IE00B5MMRT66.SGD","LU0314109678.HKD","BK1521","LU1226287792.SGD","IE00B543WZ88.USD","LU0315179316.USD","520880","LU0072913022.USD","BK1161","LU1226287875.USD","FLHK","BK1191","IE00BZ08YS42.EUR","159316","LU1807302812.USD","KURE","SG9999004220.SGD","LU1008478684.HKD","06978","LU1951186391.HKD","LU0880133367.SGD","LU1960683339.HKD","LU0067412154.USD","MEDX","HK0000165453.HKD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664463098","title":"摩根大通投行联席负责人：并购交易业务有望迎来创纪录年份。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664463098","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664463098?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 02:58","pubTimestamp":1788375516,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IEFN","IBBQ","VXF","IYH","DFMC","AAUM","PGF","GTPE","BK4582","RSPH","PEVC","MMID","TMED","PSP","TBXU","UYG","FFSM","BK4588","BK4585","PBPH","CANC","RFG","MNA","XLFI","ACTV","PRVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810334","title":"首个国产IL-17A/F双靶点抑制剂获批，这一40年来“有研究无产品”的靶点迎临床突破｜掘金创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810334","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664810334?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 22:37","pubTimestamp":1788359868,"startTime":"0","endTime":"0","summary":"半月临床试验动向根据医药魔方提供的数据，8月15日至8月28日，国家药品监督管理局药品审评中心（CDE）共披露195条创新药临床试验登记信息，其中53条为Ⅱ期及以上的关键临床试验。8月15日至8月28日，国家药品监督管理局批准8款创新药上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023863103683.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023863103683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","MEDX","159992","BK1161","IBBQ","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664081495","title":"创新药半年报冰火两重天：百济神州一款药卖了161亿元、六成药企还在求生 ，“卖药”仍是终极命题","url":"https://stock-news.laohu8.com/highlight/detail?id=2664081495","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664081495?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 20:48","pubTimestamp":1788353325,"startTime":"0","endTime":"0","summary":"2026年上半年财报季收官，中国创新药产业交出了一份分水岭式的答卷。行业正在告别烧钱讲故事的阶段，走向赚钱才是硬道理的价值兑现期。这种转变并非行业普涨，而是由商业化放量、出海授权爆发、资金来源多元化三重动力共同推动的分化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862982990.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862982990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","ONC","LU0588546209.SGD","BK1583","BK4139","BK1161","IBBQ","LU1719994722.HKD","LU1770034418.SGD","LU2328871848.SGD","06160","LU1251922891.USD","BK0239","BK4588","06978","MEDX","BK1500","LU1969619763.USD","LNGR","159992","LU0828237510.HKD","BK1588","KURE","BK1574","LU0228659784.USD","688235","LU0307460666.USD","BK4526","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811365","title":"欧康维视生物-B(01477)：OT-211 III期临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811365","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811365?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 20:14","pubTimestamp":1788351299,"startTime":"0","endTime":"0","summary":"欧康维视生物-B公布，OT-211在中华人民共和国开展的III期临床试验已于近日完成合共398名患者的入组。2026年3月，OT-211于中国的III期临床试验完成首例患者入组，标志着 OT-211在中国的临床开发取得重要里程碑进展，并体现了本集团致力于为DED患者推进创新疗法。OT-211已于2025年5月28日获FDA批准用于治疗DED的体征及症状。本次OT-211的成功入组标志着公司与Alcon集团在新药开发领域也形成了强有力的合作与绑定，为后续新药共同探索与开发打下基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","BK1574","BMED","PSYK","IBBJ","IBBQ","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664194548","title":"安进（AMGN）罕见病药物Tavneos将于27年3月1日被彻底撤销英国上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2664194548","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664194548?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 19:59","pubTimestamp":1788350357,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英国药品监管机构MHRA宣布，暂停安进（AMGN）罕见病药物Avacopan Vifor（原商品名Tavneos）用于新患者，监管认定支撑该药物获批的关键临床试验数据已不可靠。该药2022年在英国获批，用于治疗两种罕见血管炎症自身免疫病。安进持有美国地区权益，由CSL集团（CSLLY）旗下CSLVifor负责英国等海外市场销售。新规9月1日落地，不再允许新患者启用该药物；为保障现有患者安全，设置6个月过渡用药期，2027年3月1日将彻底撤销其英国上市许可，现有患者可在此期间逐步更换替代治疗方案。安进方面公开表示不认可监管机构的决定，担忧该举措会对罕见病患者造成负面影响。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305627","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","AZNH","AMGN","IE00B4R5TH58.HKD","LU0122379950.USD","LU1571399168.USD","PBE","LU2112291526.USD","BK4533","LU0058720904.USD","LU2468319806.SGD","LU2089984988.USD","PJP","BK4588","IBB","LU0320765992.SGD","LU1057294990.SGD","LU2242652126.USD","LU0289739699.SGD","LU0868494617.USD","LU1061106388.HKD","BK4581","SG9999001440.SGD","TBXU","IE00BFTCPJ56.SGD","IPOS","BK4566","LU1983299246.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4139","LU2242646821.SGD","BBH","BIB","IBBQ","IE00B2B36J28.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4599","BK4534","BK4585","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819950","title":"海西新药：已提交自研创新药HX9428临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819950","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819950?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 19:53","pubTimestamp":1788349980,"startTime":"0","endTime":"0","summary":"9月2日，海西新药（02637）发布公告，公司自主研发的创新药项目HXP056之候选药物分子HX9428，已于2026年8月31日正式向国家药监局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。HX9428是海西新药自主研发的全新口服小分子创新药物，拟用于治疗nAMD、DME及RVO等血管性视网膜相关疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862943252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862943252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","PSYK","BK1161","IBBJ","IBBQ","BMED","BK1574","MDTX","LNGR","159992","MEDX","06978","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815045","title":"诺华集团：高效口服BTK抑制剂瑞米布替尼在III期RMS临床试验中显著降低复发率 安全性表现良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815045","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815045?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 19:11","pubTimestamp":1788347485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","IE0002141913.USD","BK4532","IE00BJJMRZ35.SGD","NVS","BK4588","IE00B2B36J28.USD","IE00B4R5TH58.HKD","PPH","BK4578","MDTX","MEDX","IE00BFTCPJ56.SGD","LU0208291251.USD","LU0320765489.SGD","IE00BJT1NW94.SGD","IBBJ","LU0070302665.USD","PSYK","BK4007","IE0009355771.USD","LU0211331839.USD","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664818429","title":"众生药业(002317.SZ)：昂拉地韦片新增适应症临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664818429","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664818429?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 17:59","pubTimestamp":1788343190,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布公告，近日，公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新药物昂拉地韦片新增适应症“治疗高并发症风险甲型流感”的药物临床试验申请获得国家药品监督管理局(NMPA)受理，并收到《受理通知书》。据悉，昂拉地韦片是具有明确作用机制和全球自主知识产权的全球首款流感RNA聚合酶PB2蛋白抑制剂，已于2025年5月获NMPA批准上市。此次昂拉地韦片新增适应症拟开展III期临床研究入组12岁及以上青少年和成人甲型流感参与者，评估昂拉地韦片治疗甲型流感病毒感染且存在流感相关并发症高风险参与者的有效性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BMED","BK0239","002317","BK0188","IBBJ","PSYK","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897083","title":"国家药监局正式启动滴眼剂一致性评价工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897083","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664897083?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 17:13","pubTimestamp":1788340392,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","MDTX","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664891714","title":"高盛9月“确信名单”更新：美股纳入福泰制药(VRTX.US) 欧股力推莱茵、Adyen和塔兰克斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891714","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664891714?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 15:20","pubTimestamp":1788333621,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LU0868494617.USD","BK4127","LU0251131958.USD","LU0432979614.USD","LU2471134952.CNY","LU0868494708.USD","IE00B19Z9P08.USD","LU1144417596.USD","SG9999001176.SGD","LU1668664300.SGD","TBXU","LU0289739699.SGD","IE00BZ9MQY76.HKD","LU1791807156.HKD","LU0096364046.USD","BK4550","IBBQ","IBB","LU2237443978.SGD","LU1674673691.USD","IDNA","IE0002141913.USD","IE0009355771.USD","IEV","LU1868837300.USD","BK4588","PBE","LU2237438978.USD","BK4533","BIB","LU2462157665.USD","LU1868836591.USD","LU2471134523.USD","LU2468319806.SGD","LU2324357040.USD","GNMX","IE00BJJMRZ35.SGD","LU2237443549.SGD","VRTX","LU0942090050.USD","LU1868836914.USD","IE00B19Z9Z06.USD","BBH","LU0061475181.USD","SG9999001176.USD","GSX","VXUS","LU2456880835.USD","VGK"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":9,"totalSize":201,"code":"91000000","status":"200"}]}}